Medicinal Cannabis NZ Guide

How to read medicinal-cannabis evidence

How to read medicinal-cannabis evidence. Separate cannabinoids, products, routes, outcomes and study designs. The page must give the reader a usable method, che

Reading medicinal-cannabis evidence is not like reading evidence for a single drug. A cannabis product is not one medicine; it is a combination of active compounds, a route of administration, a dose, and a specific condition. When you read a study or a claim, you need to separate four things before you can judge whether it applies to you or your patient: the condition being treated, the outcome measured, the preparation used, and the quality of the evidence. If any of these four is missing, the claim is incomplete and should not guide a prescribing decision.

This page gives you a method for reading that evidence, a checklist to apply to any study or product claim, and the regulatory context that determines what can legally be prescribed in New Zealand under the Misuse of Drugs Act 1975 and the Medicinal Cannabis Scheme (Ministry of Health, 2023).

The one rule: name the condition, outcome, preparation, and evidence quality

Every useful statement about medicinal cannabis should be able to answer four questions:

  1. Which condition? (e.g., chronic neuropathic pain, not “pain”)
  2. Which outcome? (e.g., 30% reduction in pain score, not “feels better”)
  3. Which preparation? (e.g., CBD oil 10 mg/mL, THC flower 22%, not “cannabis”)
  4. What evidence quality? (e.g., systematic review, RCT, expert opinion, anecdote)

If a claim cannot answer all four, treat it as marketing, not evidence. This rule is the core of the page.

1. Start with the regulatory frame

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), legalises access via a prescription from a medical practitioner. Products must meet GMP standards and be approved by the Ministry of Health (New Zealand Ministry of Health, 2020). The scheme does not legalise recreational use, home growing, or the purchase of unregulated products. A prescription is required for all medicinal cannabis products, including CBD-only products, and the raw flower is prescribed and dispensed through a pharmacy, not a dispensary.

The most common error newcomers make is assuming “legal medicinal cannabis” means they can smoke raw plant material or buy unregulated oils. Under the Medicinal Cannabis Scheme, the legal product is a manufactured pharmaceutical that meets GMP standards and is approved by the Ministry of Health. This page gives you a method to read the evidence behind those products, so you can have a more informed conversation with a prescriber.

The core method: separate the four variables

Every claim about medicinal cannabis should be read through four separate lenses. When you mix them up, the evidence seems contradictory. When you separate them, most apparent conflicts dissolve.

1. The condition (what is being treated). Evidence for chronic pain does not transfer to epilepsy, anxiety, or insomnia. A study that shows benefit for one condition says nothing about another. Always ask: which condition was studied?

2. The outcome (what was measured). “Pain” can mean pain intensity at rest, pain on movement, sleep disruption, or quality of life. A product may improve one and not another. Always ask: which outcome was measured, and how was it measured (e.g., a 0-10 scale, a questionnaire, a sleep diary)?

3. The preparation (which cannabinoids, which route, which dose). Evidence for a high-CBD oil does not transfer to a high-THC flower, and evidence for an inhaled product does not transfer to an oral oil. The label must state: CBD content, THC content, ratio, form (flower/oil/capsule), and route (inhaled, sublingual, oral). If the evidence does not name these, it is not about the product you are holding.

4. The outcome (what was measured). Pain reduction, anxiety score, seizure frequency, sleep quality, quality of life, adverse events. The same product can be effective for one outcome and ineffective for another. Always ask: “What exactly changed, and how was it measured?”

5. Evidence quality. Distinguish systematic reviews and meta-analyses (highest), randomised controlled trials (high), open-label and observational studies (moderate), case reports (low), and marketing claims (not evidence). The New Zealand Ministry of Health and Medsafe do not rank products for efficacy; they regulate quality and access. Peer-reviewed clinical guidance, such as the NZ Formulary, is the most practical source for prescribers.

6. Study design and relevance. A high-quality trial for chronic pain will not necessarily predict results for epilepsy, anxiety, or sleep. The same product, dose, route, and outcome must be compared. Relevance to the New Zealand setting (product availability, legal status, patient population) matters as much as study quality.

7. Conflicts of interest and funding. Industry-funded studies tend to report larger effect sizes; check the funding source and whether the authors have received cannabis-industry payments. Government-funded or independent academic reviews are more reliable.

8. Product-specific evidence, not class effects. Cannabinoids are not interchangeable. A trial of a high-THC oil cannot be generalised to a high-CBD oil. The route (inhaled vs oral), the product, and the chemotype determine the result.

9. Outcome and duration. Evidence for short-term outcomes (e.g., 4 weeks of pain relief) cannot be extrapolated to years of use. Ask whether the study measured pain, sleep, function, quality of life, or anxiety. A change in one does not imply a change in the other.

10. Safety and adverse events. Every study must be checked for how adverse events were reported, because mild sedation is common, but serious events are rare; in practice, the risk profile differs by product, route and dose.

11. Source hierarchy. NZ Formulary and Healthify are the local gateways. Medsafe approves products. Peer-reviewed clinical guidance and systematic reviews from Cochrane, the US National Academies, or the Australian TGA are higher-quality sources than patient forums or vendor websites.

12. Practical application. When a clinician or patient reads a study, they should ask: is the product named, is the dose specified, is the outcome clinically meaningful, and is the evidence quality stated? If a claim lacks these, it is marketing, not evidence.

13. What to do next. The reader must take the summary to a clinician; the clinician decides if a prescription is appropriate. The page is not a prescription and does not replace a consultation.

14. The real-world context. The legal product is a manufactured pharmaceutical; raw flower is prescribed and dispensed through a pharmacy; the scheme is under the Misuse of Drugs Act; products must be GMP-certified and approved by the Ministry of Health; patients cannot legally smoke raw plant material; the scheme does not legalise recreational use.

15. Key regulatory figures. The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, and the scheme began accepting licence applications on 1 April 2020. From 31 January 2020, the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set out the legal framework. The Ministry of Health runs the scheme through the Medicinal Cannabis Agency (MCA). Products must meet GMP standards and be approved by the Ministry of Health. The Minister of Health can set a maximum price for controlled drug cannabis products under the Misuse of Drugs Act 1975.